• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

X 组分泌型磷脂酶 A2 对低密度脂蛋白的强力修饰与巨噬细胞泡沫细胞形成有关。

Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.

作者信息

Hanasaki Kohji, Yamada Katsutoshi, Yamamoto Shigenori, Ishimoto Yoshikazu, Saiga Akihiko, Ono Takashi, Ikeda Minoru, Notoya Mitsuru, Kamitani Shigeki, Arita Hitoshi

机构信息

Shionogi Research Laboratories, Shionogi and Co., Ltd., Sagisu 5-12-4, Fukushima-ku, Osaka 553-0002, Japan.

出版信息

J Biol Chem. 2002 Aug 9;277(32):29116-24. doi: 10.1074/jbc.M202867200. Epub 2002 May 20.

DOI:10.1074/jbc.M202867200
PMID:12021277
Abstract

The deposition of cholesterol ester within foam cells of the artery wall is fundamental to the pathogenesis of atherosclerosis. Modifications of low density lipoprotein (LDL), such as oxidation, are prerequisite events for the formation of foam cells. We demonstrate here that group X secretory phospholipase A2 (sPLA2-X) may be involved in this process. sPLA2-X was found to induce potent hydrolysis of phosphatidylcholine in LDL leading to the production of large amounts of unsaturated fatty acids and lysophosphatidylcholine (lyso-PC), which contrasted with little, if any, lipolytic modification of LDL by the classic types of group IB and IIA secretory PLA2s. Treatment with sPLA2-X caused an increase in the negative charge of LDL with little modification of apolipoprotein B (apoB) in contrast to the excessive aggregation and fragmentation of apoB in oxidized LDL. The sPLA2-X-modified LDL was efficiently incorporated into macrophages to induce the accumulation of cellular cholesterol ester and the formation of non-membrane-bound lipid droplets in the cytoplasm, whereas the extensive accumulation of multilayered structures was found in the cytoplasm in oxidized LDL-treated macrophages. Immunohistochemical analysis revealed marked expression of sPLA2-X in foam cell lesions in the arterial intima of high fat-fed apolipoprotein E-deficient mice. These findings suggest that modification of LDL by sPLA2-X in the arterial vessels is one of the mechanisms responsible for the generation of atherogenic lipoprotein particles as well as the production of various lipid mediators, including unsaturated fatty acids and lyso-PC.

摘要

胆固醇酯在动脉壁泡沫细胞内的沉积是动脉粥样硬化发病机制的基础。低密度脂蛋白(LDL)的修饰,如氧化,是泡沫细胞形成的先决条件。我们在此证明X组分泌型磷脂酶A2(sPLA2-X)可能参与了这一过程。发现sPLA2-X可诱导LDL中磷脂酰胆碱的有效水解,导致大量不饱和脂肪酸和溶血磷脂酰胆碱(溶血PC)的产生,这与经典的IB组和IIA组分泌型磷脂酶A2对LDL的脂解修饰极少形成对比。与氧化LDL中载脂蛋白B(apoB)的过度聚集和片段化相反,用sPLA2-X处理导致LDL负电荷增加,而apoB几乎没有修饰。sPLA2-X修饰的LDL被有效地摄取到巨噬细胞中,诱导细胞胆固醇酯的积累和细胞质中非膜结合脂滴的形成,而在氧化LDL处理的巨噬细胞的细胞质中发现了多层结构的广泛积累。免疫组织化学分析显示,在高脂喂养的载脂蛋白E缺陷小鼠动脉内膜的泡沫细胞病变中,sPLA2-X有明显表达。这些发现表明动脉血管中sPLA2-X对LDL的修饰是产生致动脉粥样硬化脂蛋白颗粒以及包括不饱和脂肪酸和溶血PC在内的各种脂质介质产生的机制之一。

相似文献

1
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.X 组分泌型磷脂酶 A2 对低密度脂蛋白的强力修饰与巨噬细胞泡沫细胞形成有关。
J Biol Chem. 2002 Aug 9;277(32):29116-24. doi: 10.1074/jbc.M202867200. Epub 2002 May 20.
2
Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans.V组分泌型磷脂酶A2修饰的低密度脂蛋白通过一种不依赖于清道夫受体A和CD36且涉及细胞蛋白聚糖的过程促进泡沫细胞形成。
J Biol Chem. 2005 Sep 23;280(38):32746-52. doi: 10.1074/jbc.M502067200. Epub 2005 Jul 21.
3
Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation.V组分泌型磷脂酶A2对低密度脂蛋白的水解会导致颗粒自发聚集,并促进巨噬细胞泡沫细胞的形成。
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):762-7. doi: 10.1161/01.ATV.0000122363.02961.c1. Epub 2004 Feb 12.
4
Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions.V组和X组分泌型磷脂酶A2诱导的高密度脂蛋白修饰与其抗动脉粥样硬化功能降低有关。
Biochim Biophys Acta. 2003 Oct 21;1642(3):129-38. doi: 10.1016/s0167-4889(03)00120-4.
5
Hawthorn leaf flavonoids alleviate the deterioration of atherosclerosis by inhibiting SCAP-SREBP2-LDLR pathway through sPLA2-ⅡA signaling in macrophages in mice.山楂叶黄酮通过抑制小鼠巨噬细胞中sPLA2-ⅡA信号通路的SCAP-SREBP2-LDLR途径减轻动脉粥样硬化的恶化。
J Ethnopharmacol. 2024 Jun 12;327:118006. doi: 10.1016/j.jep.2024.118006. Epub 2024 Mar 3.
6
Mouse group X secretory phospholipase A2 induces a potent release of arachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 receptor.小鼠X组分泌型磷脂酶A2可诱导脾细胞大量释放花生四烯酸,并作为磷脂酶A2受体的配体发挥作用。
Arch Biochem Biophys. 2000 Sep 1;381(1):31-42. doi: 10.1006/abbi.2000.1977.
7
Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition.巨噬细胞特异性过表达IIa型分泌型磷脂酶A2会增加动脉粥样硬化并增强胶原蛋白沉积。
J Lipid Res. 2005 Feb;46(2):201-10. doi: 10.1194/jlr.M400253-JLR200. Epub 2004 Dec 1.
8
A modification of apolipoprotein B accounts for most of the induction of macrophage growth by oxidized low density lipoprotein.载脂蛋白B的一种修饰作用是氧化型低密度脂蛋白诱导巨噬细胞生长的主要原因。
J Biol Chem. 1999 Apr 16;274(16):10903-10. doi: 10.1074/jbc.274.16.10903.
9
Differences between group X and group V secretory phospholipase A(2) in lipolytic modification of lipoproteins.X 组和 V 组分泌型磷脂酶 A(2)在脂蛋白的脂解修饰方面的差异。
Cell Mol Biol Lett. 2012 Sep;17(3):459-78. doi: 10.2478/s11658-012-0019-2. Epub 2012 Jun 13.
10
Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.对III型分泌型磷脂酶A2转基因小鼠的分析揭示了该酶在血浆脂蛋白修饰、巨噬细胞泡沫细胞形成和动脉粥样硬化中的潜在作用。
J Biol Chem. 2008 Nov 28;283(48):33483-97. doi: 10.1074/jbc.M804628200. Epub 2008 Sep 18.

引用本文的文献

1
A human stomach cell type transcriptome atlas.人类胃细胞类型转录组图谱。
BMC Biol. 2024 Feb 14;22(1):36. doi: 10.1186/s12915-024-01812-5.
2
Regulatory Roles of Phospholipase A Enzymes and Bioactive Lipids in Mast Cell Biology.磷脂酶 A 酶和生物活性脂质在肥大细胞生物学中的调控作用。
Front Immunol. 2022 Jun 27;13:923265. doi: 10.3389/fimmu.2022.923265. eCollection 2022.
3
Understanding the role of myoglobin content in Iberian pigs fattened in an extensive system through analysis of the transcriptome profile.通过转录组谱分析了解在粗放系统中育肥的伊比利亚猪的肌红蛋白含量的作用。
Anim Genet. 2022 Jun;53(3):352-367. doi: 10.1111/age.13195. Epub 2022 Mar 30.
4
Lipid Droplets, Phospholipase A, Arachidonic Acid, and Atherosclerosis.脂滴、磷脂酶A、花生四烯酸与动脉粥样硬化
Biomedicines. 2021 Dec 13;9(12):1891. doi: 10.3390/biomedicines9121891.
5
Atherosclerosis: integration of its pathogenesis as a self-perpetuating propagating inflammation: a review.动脉粥样硬化:作为一种自我持续进展性炎症的发病机制整合:综述
Cardiovasc Endocrinol Metab. 2019 Jun;8(2):51-61. doi: 10.1097/XCE.0000000000000172. Epub 2019 May 15.
6
Group IID, IIE, IIF and III secreted phospholipase As.I 型组、II 型组 IIE、IIF 和 III 型分泌型磷脂酶 A。
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun;1864(6):803-818. doi: 10.1016/j.bbalip.2018.08.014. Epub 2018 Aug 31.
7
Design of Selective sPLA-X Inhibitor (-)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1-indol-1-yl]pyridine-2-yl}propanoic Acid.选择性分泌型磷脂酶A-X抑制剂(-)-2-{2-[氨基甲酰基-6-(三氟甲氧基)-1-吲哚-1-基]吡啶-2-基}丙酸的设计
ACS Med Chem Lett. 2018 Jun 23;9(7):600-605. doi: 10.1021/acsmedchemlett.7b00507. eCollection 2018 Jul 12.
8
Metabolic profiling of plasma from cardiac surgical patients concurrently administered with tranexamic acid: DI-SPME-LC-MS analysis.同时接受氨甲环酸治疗的心脏外科手术患者血浆的代谢谱分析:直接浸入式固相微萃取-液相色谱-质谱联用分析
J Pharm Anal. 2014 Feb;4(1):6-13. doi: 10.1016/j.jpha.2013.03.002. Epub 2013 Apr 11.
9
Metabolic regulation by secreted phospholipase A.分泌型磷脂酶A对代谢的调节
Inflamm Regen. 2016 May 21;36:7. doi: 10.1186/s41232-016-0012-7. eCollection 2016.
10
Discovery of AZD2716: A Novel Secreted Phospholipase A (sPLA) Inhibitor for the Treatment of Coronary Artery Disease.AZD2716的发现:一种用于治疗冠状动脉疾病的新型分泌型磷脂酶A(sPLA)抑制剂。
ACS Med Chem Lett. 2016 Aug 9;7(10):884-889. doi: 10.1021/acsmedchemlett.6b00188. eCollection 2016 Oct 13.